Abstract
Dyslipidemia is common in patients with chronic kidney disease (CKD), and previous reports indicate that a significant number of CKD patients with dyslipidemia do not receive statin therapy. This article reviews two recent meta-analyses on statin therapy in CKD which summarize results from randomized controlled trials that have reported on hard clinical outcomes and major adverse events. Despite differences in methodology, both meta-analyses show that statin therapy is safe and effective in preventing mortality and major cardiovascular events in non-dialysis-dependent CKD patients. However, there is very limited evidence to support the use of statins in patients on dialysis, and statin therapy was not found to be effective in reducing the risk of kidney failure or decline in kidney function.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
